After a very tough nine months, Galapagos NV has laid the foundations on the road to recovery by refocusing its research areas, targeting €150m in savings and seeking out late-stage assets to fill the gap between its approved rheumatoid arthritis drug Jyseleca and the rest of the pipeline.
Bart Filius, Galapagos president, mapped out the Belgian biotech's strategy to Scrip after the completion of a review of the...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?